Rapid Structural and Functional Improvements in Following 0.19 mg Fluocinolone Acetonide (FAc) Implant in Diabetic Macular Edema Patients With Poor Visual Acuity: 12-month Audit Results From United Arab Emirates
试验速览
- 阶段
- 不适用
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- BCVA
研究概览
简要总结
The Health Authority - Abu Dhabi (HAAD) approved the reimbursement of the slow release FAc implant (ILUVIEN) and it is now available for the treatment of diabetic macular edema (DME) in persons who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. We performed a retrospective 12-month audit to assess the efficacy and safety of the FAc implant in our clinical practice.
详细描述
Twenty patients with pseudophakic lenses, treated with ILUVIEN, were investigated to evaluate functional and anatomical characteristics and outcomes (visual acuity [VA; ETDRS letters score], central macular thickness [CMT] and intraocular pressure [IOP]) at baseline, weeks 2-4 and months 3, 6 and 12 months.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pseudophakic
排除标准
- •Other causes of macular edema.
- •Know case of gaucoma
研究组 & 干预措施
1
patients treated with 0.19 mg fluocinolone acetonide (FAc) implant for 12 months
干预措施: 0.19 mg fluocinolone acetonide (FAc) implant (Device)
结局指标
主要结局
BCVA
时间窗: 12 months
best corrected visual acuity
次要结局
- CMT(12 months)
- IOP(12 months)
研究者
Ahmed Elbarky
assistant professor of ophthalmologyu
Benha University